Alnylam Pharmaceuticals, Inc. with ticker code (ALNY) now have 25 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $400.00 and $160.50 and has a mean target at $289.58. Now with the previous closing price of $274.91 this is indicating there is a potential upside of 5.3%. The 50 day MA is $263.25 and the 200 day moving average is $195.18. The company has a market capitalization of 35.31B. Currently the stock stands at: $275.03 USD
The potential market cap would be $37,192,797,257 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $18.62 and a 1.73% return on assets.
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes five marketed products and over ten clinical programs, including several in late-stage development, across four strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran). ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase 1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.
